Close X
Monday, November 25, 2024
ADVT 
International

Extra safety scrutiny planned as virus vaccine worries grow

Darpan News Desk The Canadian Press, 14 Oct, 2020 11:00 PM
  • Extra safety scrutiny planned as virus vaccine worries grow

Facing public skepticism about rushed COVID-19 vaccines, U.S. health officials are planning extra scrutiny of the first people vaccinated when shots become available — an added safety layer experts call vital.

A new poll suggests those vaccine fears are growing. With this week's pause of a second major vaccine study because of an unexplained illness — and repeated tweets from President Donald Trump that raise the spectre of politics overriding science — a quarter of Americans say they won't get vaccinated. That's a slight increase from 1 in 5 in May.

The poll from The Associated Press-NORC Center for Public Affairs Research found only 46% of Americans want a COVID-19 vaccine and another 29% are unsure.

More striking, while Black Americans have been especially hard-hit by COVID-19, just 22% say they plan to get vaccinated compared with 48% of white Americans, the AP-NORC poll found.

“I am very concerned about hesitancy regarding COVID vaccine,” said Dr. William Schaffner, a vaccine specialist at Vanderbilt University who says even the primary care doctors who'll need to recommend vaccinations have questions.

“If the politicians would stand back and let the scientific process work, I think we’d all be better off,” he added.

The stakes are high: Shunning a COVID-19 shot could derail efforts to end the pandemic — while any surprise safety problems after one hits the market could reverberate into distrust of other routine vaccines.

On top of rigorous final testing in tens of thousands of people, any COVID-19 vaccines cleared for widespread use will get additional safety evaluation as they're rolled out. Among plans from the Centers for Disease Control and Prevention: Texting early vaccine recipients to check how they're feeling, daily for the first week and then weekly out to six weeks.

Any vaccine before Election Day is extremely unlikely. Over Trump’s objections, the Food and Drug Administration issued clear safety and effectiveness standards that shots must meet -- and Commissioner Stephen Hahn insists career scientists, not politicians, will decide each possible vaccine's fate only after all the evidence is debated at a public meeting.

Dr. Anthony Fauci, the top U.S. infectious diseases expert, says that should be reassuring because it means scientists like himself will see all the evidence.

“So the chances of there being secret hanky-panky are almost zero, because everything is going to be transparent,” he told The AP.

Here are some things to watch as vaccines get closer to the finish line.

THERE’S STILL NO GUARANTEE

Furthest along in final-stage testing in the U.S. are a vaccine candidate made by Pfizer Inc. and Germany’s BioNTech, and another developed by Moderna Inc. and the National Institutes of Health.

Fauci says “the best bet” is that data about whether one or both work will emerge sometime in November or December.

How soon depends on an independent Data Safety and Monitoring Board -- the only group that can peek at the data before the study’s finished. At pre-set time points, the board can analyze the number of infections occurring so far among participants and decide if the study should be stopped early because of strong evidence the vaccine works, or if it’s failing, or that it’s too soon to know.

EFFECTIVENESS IS ONLY HALF THE STORY

The DSMB also watches for side effects. Many vaccines cause temporary side effects like fever, chills and other flu-like symptoms.

Two other vaccine candidates in final-stage testing in the U.S. have been temporarily halted to investigate additional safety questions. Johnson & Johnson paused its study this week after learning of “an unexplained illness” in one participant, and the company expects it will take a few days to learn if the problem is a side effect or a coincidence.

But testing of AstraZeneca's vaccine has been on hold in the U.S. for over a month after news emerged of neurological illnesses in two British participants. Regulators let AstraZeneca's study resume in Britain and several other countries, but FDA still is deciding.

Stopping those studies “shows you that the system that we have in place to monitor the safety of the vaccines and the rigorous conduct of the trial is in place and it's working,” Schaffner said.

Looking back at vaccines for other diseases, side effects show up within two to three months, said FDA vaccine chief Dr. Peter Marks.

So FDA told COVID-19 vaccine makers: If they seek “emergency use authorization” to get their shot to market faster than normal, they still would have to track half the participants for two months after the last dose.

Then it would take FDA several weeks of breakneck work to decide if a COVID-19 vaccine really was suitable for emergency use, Marks said. In contrast, evaluating an application for full approval could take months, as FDA officials comb through fuller records of how participants fared.

EXTRA SAFETY STEPS

Even large final tests won't catch a side effect that happens in, say, 1 in 100,000 people. So there's an early warning system that monitors every vaccine sold in the U.S. to spot unsuspected side effects.

“It’s a system that has served us very well,” said Dr. Bruce Gellin of the Sabin Vaccine Institute, who once directed the government’s National Vaccine Program Office. “But for this unprecedented vaccination campaign, we need to expand” that monitoring.

Once the FDA clears a vaccine, health workers and other essential workers are expected to get the first doses — and they'll have to sign an agreement to do so that includes their cell number and email. The CDC will use those registrations to check how the vaccinated are feeling.

Any health complaint bad enough that they missed work, couldn’t do a normal activity or had to seek medical care gets a follow-up probe, said CDC’s Dr. Tom Shimabukuro.

Separately, the FDA will be checking giant databases of insurance claims and electronic medical records, to see if people who received vaccine also have an uptick in health care.

And states including New York, Rhode Island and Virginia are forming advisory committees to review the safety of any COVID-19 vaccines that pass FDA.

MORE International ARTICLES

Microsoft CEO Satya Nadella Tops Fortune's Businessperson Of The Year 2019 List

Microsoft CEO Satya Nadella Tops Fortune's Businessperson Of The Year 2019 List
Fortune's annual list features 20 business leaders "who tackled audacious goals, overcame impossible odds, found creative solutions".    

Microsoft CEO Satya Nadella Tops Fortune's Businessperson Of The Year 2019 List

Hong Kong Court Extradites Punjab Fugitive Ramanjit Singh Romi

Hong Kong Court Extradites Punjab Fugitive Ramanjit Singh Romi
A Hong Kong court has extradited fugitive Ramanjit Singh, alias Romi, the key conspirator in Punjab's Nabha jail break as well as several other major crimes, officials said on Wednesday.  

Hong Kong Court Extradites Punjab Fugitive Ramanjit Singh Romi

Indian Man Charged With Sexual Assault While Working In Afghanistan As US Contractor

Indian Man Charged With Sexual Assault While Working In Afghanistan As US Contractor
An Indian man working for the US in Afghanistan has been brought to Washington to be tried on charges that he allegedly sexually assaulted an American woman there, according to Assistant Attorney General Brian Benczkowski.

Indian Man Charged With Sexual Assault While Working In Afghanistan As US Contractor

Houston Police Honour Fallen Sikh Policeman Sandeep Singh Dhaliwal, Change Dress Code Policy

In honour of fallen Indian-American Sikh police officer Sandeep Singh Dhaliwal, the Houston Police Department has changed its dress code policy to allow the minority community members to represent their faith while on duty.

Houston Police Honour Fallen Sikh Policeman Sandeep Singh Dhaliwal, Change Dress Code Policy

2 Indian-Origin Drivers - Gurnam Singh, Jatinder Kumar - In Line For UK’s Top Bus Driver Award

Two Indian-origin drivers have made it to a six-member shortlist to crown the Top National Bus Driver at the UK Bus Awards next week.

2 Indian-Origin Drivers - Gurnam Singh, Jatinder Kumar - In Line For UK’s Top Bus Driver Award

Indian Couple 1st To Be Convicted Of Labour Trafficking In Singapore

Indian Couple 1st To Be Convicted Of Labour Trafficking In Singapore
In the first conviction of a labour trafficking case in Singapore, an Indian couple was convicted of abusing their power to exploit employees by various means including verbal abuse, financial penalties and controlling their movements, a media report said on Saturday.

Indian Couple 1st To Be Convicted Of Labour Trafficking In Singapore